Testosterone Cypionate Fertility Suppression: A Severity Grading Rubric

Why Testosterone Cypionate Suppresses Fertility

Testosterone cypionate causes fertility suppression because it replaces endogenous testosterone production and shuts down the signals that drive sperm production. The hypothalamic-pituitary-gonadal (HPG) axis operates on a negative feedback loop: when circulating testosterone rises above the physiological set point, the hypothalamus reduces gonadotropin-releasing hormone (GnRH) pulsatility, and the anterior pituitary decreases secretion of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1].

LH normally stimulates Leydig cells to produce intratesticular testosterone (ITT), which is required at concentrations 50 to 100 times higher than serum levels to support spermatogenesis. FSH acts on Sertoli cells to maintain the seminiferous tubule microenvironment. When both gonadotropins fall to near-undetectable levels, ITT collapses by 94 to 98 percent, and sperm production slows or stops entirely [2]. A 2006 study in the Journal of Clinical Endocrinology and Metabolism measured ITT in men receiving exogenous testosterone and found reductions from a mean of 599 ng/dL to 18.6 ng/dL, well below the threshold needed for spermatogenesis [3].

This suppression is dose-independent to a degree. Even replacement doses of testosterone cypionate (100 to 200 mg every 1 to 2 weeks) produce supraphysiological troughs in some men and fully suppress gonadotropins in the majority. The WHO Male Contraceptive trials of the 1990s demonstrated that 200 mg testosterone enanthate weekly (pharmacokinetically similar to cypionate) induced azoospermia in 65 percent of participants and severe oligospermia (sperm concentration <3 million/mL) in over 90 percent within 6 months [4].

The biological lesson is straightforward. You cannot add exogenous testosterone without subtracting the endogenous signals that make sperm.

The Four-Grade Severity Rubric

Grading fertility suppression on a standardized scale helps clinicians match monitoring intensity to clinical risk. The rubric below synthesizes WHO semen analysis reference values (6th edition, 2021) with CTCAE v5.0 reproductive toxicity grading and AUA guidelines on male infertility evaluation [5][6].

Grade 1: Mild Oligospermia

Sperm concentration remains above 5 million/mL but has declined more than 50 percent from the patient's baseline. LH and FSH are suppressed but may still be detectable (LH 0.5 to 1.5 IU/L). Patients in this grade retain some reproductive potential, though time-to-conception is likely extended. This grade is most common in the first 4 to 8 weeks of testosterone cypionate use or during low-dose protocols.

Clinical action: Document the decline, counsel on reduced fecundity, and reassess at 3 months. If the patient desires fertility within the next 12 months, consider adding hCG 500 IU subcutaneously three times weekly or transitioning to a selective estrogen receptor modulator (SERM) such as clomiphene citrate 25 mg every other day [7].

Grade 2: Moderate Oligospermia

Sperm concentration is between 1 and 5 million/mL. LH and FSH are typically below 0.5 IU/L. Natural conception is unlikely without intervention. Most patients reach Grade 2 within 8 to 16 weeks of standard-dose testosterone cypionate (150 to 200 mg weekly or biweekly).

Clinical action: If fertility preservation was not addressed before starting TRT, initiate it now. Options include hCG co-therapy, addition of low-dose FSH (75 IU three times weekly) in refractory cases, or immediate sperm cryopreservation if any motile sperm remain. The 2021 AUA/ASRM guideline on male infertility explicitly warns against initiating testosterone therapy as a fertility treatment and recommends hCG or SERMs as first-line alternatives for hypogonadal men seeking conception [6].

Grade 3: Severe Oligospermia to Cryptozoospermia

Sperm concentration is <1 million/mL, or sperm are found only on centrifuged pellet analysis (cryptozoospermia). Gonadotropins are undetectable. This grade represents near-complete spermatogenic arrest and is the expected steady-state for most men after 4 to 6 months of continuous testosterone cypionate monotherapy. Data from the WHO contraceptive efficacy trials showed that 33 percent of men who did not reach azoospermia stabilized in this range [4].

Clinical action: Cryopreserve any recoverable sperm using extended preparation techniques (testicular sperm extraction may be required if ejaculated samples are persistently azoospermic). If the patient has completed family-building, document Grade 3 status and continue TRT. If future fertility is desired, discuss a structured withdrawal protocol or hCG bridging.

Grade 4: Azoospermia

No sperm detected on two consecutive semen analyses performed 2 to 4 weeks apart, with centrifuged pellet evaluation. This is confirmed azoospermia. Approximately 65 percent of men on testosterone monotherapy reach this grade by 6 months [4]. A 2019 retrospective cohort of 6,569 men in the FDA Adverse Event Reporting System (FAERS) database identified 243 reports of azoospermia associated with testosterone products, making it one of the most frequently reported reproductive adverse events [8].

Clinical action: If fertility is desired, discontinue testosterone cypionate and initiate a recovery protocol: hCG 1,500 to 3 to 000 IU three times weekly plus clomiphene citrate 25 to 50 mg daily, with semen analysis every 3 months. Recovery to at least oligospermic levels occurs in 67 percent of men within 6 months and 90 percent within 12 months according to a 2017 meta-analysis in Fertility and Sterility (N=1,549 across 12 studies), though 5 to 10 percent show persistent azoospermia at 24 months [9].

Monitoring Protocol for Each Severity Grade

Surveillance frequency should scale with severity. A baseline semen analysis before initiating testosterone cypionate is the single most important step because without it, you cannot quantify the degree of suppression or later document recovery. The 2018 AUA Guideline on Evaluation of the Infertile Male recommends two baseline semen analyses 2 to 4 weeks apart [6].

For Grade 1, repeat semen analysis at 3 and 6 months. For Grade 2, repeat at 6-week intervals until the trajectory stabilizes. Grades 3 and 4 require semen analysis only if the patient's reproductive goals change, though annual hormonal panels (LH, FSH, total testosterone, estradiol) should continue. All grades warrant a documented fertility goals assessment at least annually during TRT.

Hormonal markers alone are not sufficient. A suppressed FSH (<0.5 IU/L) strongly predicts impaired spermatogenesis, but semen analysis remains the definitive measure. A 2014 cross-sectional study of 365 men on TRT found that 23 percent of men with undetectable FSH still had residual sperm in their ejaculate, illustrating why hormonal surrogates cannot replace direct sperm counting [10].

Inhibin B is an additional biomarker that may predict recovery potential. Sertoli cells secrete inhibin B in proportion to their functional mass. Men with pre-treatment inhibin B above 80 pg/mL show faster spermatogenic recovery after testosterone cessation according to data from the Male Contraception NORMA trial [11]. While not yet part of standard guidelines, a single inhibin B measurement at baseline can inform prognosis.

Managing Fertility Suppression on Testosterone Cypionate

Three management strategies exist, and the right choice depends on the patient's timeline for conception, comfort with injectable therapies, and willingness to modify or stop TRT.

Strategy 1: Concurrent hCG. Adding human chorionic gonadotropin at 500 IU subcutaneously three times weekly maintains intratesticular testosterone and preserves spermatogenesis in many men on TRT. A 2005 study by Coviello et al. demonstrated that 250 IU hCG every other day maintained baseline ITT levels in men receiving 200 mg testosterone enanthate weekly, while 500 IU maintained ITT at 25 percent above baseline [3]. The tradeoff is cost (hCG averages $150 to $300/month without insurance), additional injections, and the risk of estradiol elevation requiring aromatase inhibitor management. "For men who want the benefits of testosterone replacement but plan to have children within a few years, concurrent low-dose hCG is the most practical fertility-sparing approach," stated Dr. Peter Schlegel, past president of the American Society for Reproductive Medicine, in the 2021 AUA/ASRM joint guideline commentary [6].

Strategy 2: SERM substitution. For men in Grade 1 or 2 who are willing to stop testosterone cypionate, switching to clomiphene citrate (25 to 50 mg daily) or enclomiphene (12.5 to 25 mg daily) raises endogenous testosterone by stimulating LH and FSH release while preserving or restoring spermatogenesis. A 2013 prospective study of 46 men who transitioned from TRT to clomiphene showed recovery of sperm concentrations above 20 million/mL in 71 percent within 3 to 6 months [12]. SERMs do not produce the same testosterone levels or symptom relief as exogenous testosterone in all patients, so this approach involves a quality-of-life tradeoff.

Strategy 3: Testosterone cessation with gonadotropin restart. For men at Grade 3 or 4 who want to conceive, the standard approach is discontinuing testosterone cypionate and starting combination gonadotropin therapy: hCG 1,500 to 3 to 000 IU three times weekly (to restore ITT) plus recombinant FSH 75 to 150 IU three times weekly (to directly stimulate Sertoli cells). "Recovery of spermatogenesis following exogenous testosterone is possible for most men, but physicians should counsel that complete recovery is not guaranteed and may take over a year," wrote Patel et al. in their 2019 review in the Journal of Urology [13]. The patient should expect a symptomatic hypogonadal window during the transition, which hCG partially mitigates.

Sperm cryopreservation before initiating TRT remains the most reliable safeguard. The cost is modest ($300 to $1,000 for initial banking plus $200 to $500 annual storage) relative to the cost of fertility treatments after prolonged azoospermia [6].

Recovery Timeline and Predictive Factors

Recovery from testosterone-induced azoospermia is not instantaneous. The spermatogenic cycle in humans takes approximately 74 days from spermatogonia to mature spermatozoa, and recovery requires re-establishment of the HPG axis before the cycle can restart.

The 2017 meta-analysis by Patel et al. pooled data from 1,549 men across 12 studies and found median recovery to a sperm concentration of 20 million/mL at 6.7 months after testosterone cessation. By 12 months, 90 percent of men had recovered at least some sperm production. Duration of prior testosterone use was the strongest predictor of recovery time: men who used TRT for <6 months recovered in a median of 3.4 months, while those with over 3 years of use required a median of 9.8 months [9].

Age also matters. Men over 45 at the time of TRT cessation showed slower recovery and a higher rate of persistent oligospermia, likely reflecting age-related decline in spermatogonial stem cell reserves [9]. Pre-treatment sperm concentration, where available, predicted the ceiling of recovery: men who had baseline concentrations above 40 million/mL were more likely to return to normozoospermia.

These numbers contain a caveat. Most recovery studies excluded men with pre-existing subfertility, prior chemotherapy exposure, or varicocele. Real-world recovery in a general TRT population may be slower.

Who Is at Highest Risk for Irreversible Suppression

A small but real percentage of men do not recover spermatogenesis. The pooled estimate from available literature is 5 to 10 percent persistent azoospermia at 2 years post-cessation [9]. Risk factors include:

• Duration of testosterone use exceeding 4 years
• Age over 50 at initiation
• Pre-existing borderline sperm parameters (concentration 10 to 15 million/mL before TRT)
• History of cryptorchidism, orchitis, or prior testicular surgery
• Concurrent use of 19-nortestosterone derivatives (nandrolone, trenbolone), which produce more profound gonadotropin suppression and have been linked to slower recovery in case series [14]

The clinical lesson for prescribers is clear. Fertility counseling before the first injection of testosterone cypionate is not optional. The Endocrine Society's 2018 Clinical Practice Guideline for Testosterone Therapy in Men with Hypogonadism specifically states: "Clinicians should inform patients that testosterone therapy suppresses spermatogenesis and that recovery is not guaranteed" [15].

FDA Labeling and Pharmacovigilance Data

The FDA-approved prescribing information for testosterone cypionate (Depo-Testosterone) lists oligospermia at high doses as an adverse reaction and includes a Warnings section noting suppression of spermatogenesis [16]. Post-marketing surveillance through FAERS has accumulated over 400 reproductive adverse event reports associated with testosterone products since 2004, including azoospermia, oligospermia, and male infertility. A 2019 pharmacovigilance analysis identified a reporting odds ratio of 15.6 for azoospermia with testosterone products compared to all other drugs in FAERS, confirming this is a disproportionately reported signal rather than background noise [8].

The American Urological Association released a formal position statement in 2018 explicitly recommending against the use of testosterone or other androgens for the treatment of male infertility, noting that prescribing testosterone to infertile men is a "well-documented but still common clinical error" [6].

Pre-Treatment Fertility Counseling Checklist

Every man of reproductive age starting testosterone cypionate should receive documented counseling covering five points. First, testosterone will suppress sperm production, often to zero. Second, recovery after stopping is probable but not certain. Third, sperm banking before starting is the most reliable insurance policy. Fourth, concurrent hCG may preserve fertility during TRT but adds cost and complexity. Fifth, if the patient is actively trying to conceive, testosterone cypionate should not be started, and a SERM or hCG monotherapy should be used instead [6][15].

A signed acknowledgment of this counseling should be part of the TRT consent process. Litigation related to testosterone-induced infertility has increased since 2015, and documentation of informed consent is a standard of care [6].

Baseline semen analysis with cryopreservation, followed by repeat semen analysis at 3 and 6 months, represents the minimum monitoring standard for any man on testosterone cypionate who has not completed family-building.